In this issue of Cell, two articles show that tumor-specific changes in HLA-mediated antigen presentation affect tumor immunogenicity and may play a role in shaping cancer cell survival.
Advances in our understanding of cancer immunology have led to the understanding that tumor survival is partially dependent upon escape from immune destruction. Therapies designed to counteract immunosuppressive signals expressed by malignant cells and the tumor microenvironment have proven remarkably successful across multiple cancer types, providing strong evidence that cytotoxic T cells are capable of identifying and eliminating cancerous cells (Sharma and Allison, 2015; Tumeh et al., 2014) . One would infer, therefore, that the immune system exerts selective pressure on a cancer throughout its development; however, this evolutionary history has been difficult to ascertain with currently available technologies because this history must be derived from inference rather than direct observation.
This issue of Cell includes two studies, by Marty et al. (2017) and McGranahan et al. (2017) , that describe the application of novel genomic techniques to characterize the role of immune selective pressures on cancer evolution. Both studies focus specifically on antigen presentation, a central component of anti-tumor immunity. All nucleated human cells display major histocompatibility complex (MHC) class I molecules on their surface, which present degraded cytosolic protein fragments in the form of 8-11 amino acid peptides for recognition by CD8+ cytotoxic T cells. MHC class I is both polygenic-encoded by the three HLA-A, HLA-B, and HLA-C genes-and highly polymorphic. This combination allows a diversity of peptides to be presented and also creates significant heterogeneity between individuals as to which antigens can be presented. Cancers cells often retain their MHC class I function and may express protein products encoded by mutated genes-termed neoantigens-that flag the cancer cell for elimination via the adaptive immune system ( Figure 1A) . One key implication of this theory is the concept of immunoediting, which posits that tumors with significant neoantigen presentation are selected against, whereas immunologically ''silent'' tumors survive and grow. The finding that tumors formed in immunodeficient mice were more immunogenic than tumors from immunocompetent mice (Shankaran et al., 2001 ) provided the first experimental evidence for this theory, but this has been harder to demonstrate in human tumors.
In the first study, Marty et al. (2017) provide strong evidence for immunoediting by evaluating the binding interaction between neoantigens and HLA proteins as a predictor of antigen presentation. They develop a novel computational scoring system to predict the likelihood that a particular antigen will be displayed via the MHC I system based on neoantigen-HLA protein-binding affinity. The greater the neoantigen-HLA-binding affinity, the higher the likelihood of class I presentation. The authors analyze The Cancer Genome Atlas (TCGA) dataset using this technique and find that individual patients are significantly more likely to have a mutation that gives rise to a neoantigen with low HLA-binding affinity, suggesting that highly presented mutations were selected against. Similarly, they show that highly recurrent oncogenic mutations generally have low HLA-binding affinities across the population, consistent with the hypothesis that an oncogenic mutation is unlikely to be adaptive unless it is also immunologically silent.
In the second study, McGranahan et al. (2017) also analyze how HLA-antigen presentation affects tumor evolution by evaluating the effect of HLA copy-number loss. Historically, the methods for calculating tumor copy-number alterations perform poorly on HLA genes because the heterogeneity of HLA loci makes alignment of the tumor reads to the human reference genome subject to frequent failure. The authors overcome this obstacle by developing a novel methodology called LOHHLA that calculates HLA copy number by aligning the tumor reads to the germline HLA sequence. When they apply this method to the TRACERx cohort of 90 sequenced non-small cell lung cancer (NSCLC) samples, they find that as many as 40% of tumors exhibit loss of heterozygosity (LOH) of at least one HLA allele. The frequency of copy-number loss is greater than predicted by random chance and is associated with both an increase in neoantigens predicted to bind to the lost HLA allele and with an increase in the overall number of subclonal mutations in patients with adenocarcinoma. The authors propose that the observed increase in neoantigen load is due to compromised MHC I antigen presentation stemming from HLA LOH. They concluded that HLA LOH provides a selective advantage to cancers and allows for the outgrowth of subclones with increased neoantigen load.
These studies provide compelling evidence that antigen presentation shapes the evolutionary history of a tumor by mediating neoantigen immunosurveillance (Figures 1B and 1C) . They also provide insight into the complexity of the temporal sequence of cancer-immune interactions during the natural history of a malignancy. Marty et al. (2017) provide evidence that the immune system shapes tumor development early on by exerting negative selective pressure on highly presented oncogenic driver mutations. Conversely, McGranahan et al. (2017) show that HLA LOH is often limited to subclonal or spatially isolated populations, leading the authors to conclude that HLA LOH occurs later in tumor development as a means of ongoing adaptation to local microenvironments. These discrepant findings highlight the complexity of tumor-immune interactions, which appear to change throughout the natural history of a cancer as tumors employ a variety of tools to adapt to ongoing immune selective pressure (Schreiber et al., 2011) . They also highlight the versatility of cancer immune evasion, which will likely be an ongoing challenge to current immunotherapeutic approaches. More studies with serial biopsy and analysis are needed to clarify the temporal sequence of immune-related cancer evolution.
Additionally, these studies both suggest that there may be tissue-and diseasespecific mechanisms at play. McGranahan et al. (2017) do not find a clear association between neoantigen load and HLA LOH in lung squamous cell carcinoma, though it is present in adenocarcinomas. Similarly, Marty et al. (2017) find that the correlation between neoantigen-HLAbinding affinity and the presence of an associated mutation varies in strength across disease subtypes, with the highest correlation in thyroid cancer and adrenal cancers and the lowest in renal clear cell, sarcoma, and lung squamous cell. Interestingly, this latter finding contradicts the clinical observation that squamous cell and renal clear cell are among the cancers most responsive to immunotherapies. Conversely, some of the strongest associations they identified included pancreatic, rectal, and colon cancer, all of which have demonstrated significant intrinsic resistance to immunotherapies. These discrepancies suggest that there may be tissue-specific effects that require further investigation and that the immune mechanisms associated with response to checkpoint blockade may be different than the mechanisms that shape the tumor development.
Finally, it should be acknowledged that genomic analysis of antigen presentation represents only one aspect of the tumorimmune interaction. Multiple additional processes, including co-stimulatory/coinhibitory protein expression, and cytokine signaling, as well as the tumor microenvironment, also have important roles in mediating cancer immunosurveillance. Further studies that integrate these different aspects, including cell signaling networks, gene expression profiling, and cell-cell interactions, are necessary to improve our current understanding and to more effectively harness the immune system for cancer therapy. 
